HÄMOGLOBINMODULATOREN

Patent europeic · EP4126832 · Stritgà

Inscripziun en il register

Numer da publicaziun
EP4126832
Numer da la dumonda
EP21719796
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
Stritgà
Scrittira da patent
Concedì
Annunzià
26-03-2021
Publitgà
08-02-2023
Concedì
07-01-2026
Stritgà
23-10-2026
Motiv
Taxa annuala betg pajada
Classas IPC
C07D 295/192 (2006.01)
C07D 401/06 (2006.01)
A61P 7/06 (2006.01)
A61K 31/445 (2006.01)
A61K 31/5375 (2006.01)
A61K 31/54 (2006.01)
Prioritad
US 202063003104 P 31.03.2020
US 202063003106 P 31.03.2020
Dumonda PCT
PCT/US2021/024384 26.03.2021
Publicaziun PCT
WO2021/202284 07.10.2021
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 23-10-2026

    Stritgà, taxa betg pajada

    Status of protective title
    Active → Cancelled
    Cancellation date
    23.10.2026
    Cause for cancellation
    Non-payment of renewal fee

    Published in Swissreg on 23.10.2026

  2. 07-01-2026

    Concedì

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 07.01.2026

Partidas

Possessur

Global Blood Therapeutics, Inc.

South San Francisco, CA 94080, US

Inventur

LI, Zhe

South San Francisco, CA 94080, US

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.